Erlotinib entrapped in cholesterol-depleting cyclodextrin nanoparticles shows improved antitumoral efficacy in 3D spheroid tumors of the lung and the liver
Erlotinib (ERL), a tyrosine kinase inhibitor approved for therapeutic use in non-small cell
lung cancer is further researched for eventual liver cancer treatment. However, conventional …
lung cancer is further researched for eventual liver cancer treatment. However, conventional …
Erlotinib entrapped in cholesterol-depleting cyclodextrin nanoparticles shows improved antitumoral efficacy in 3D spheroid tumors of the lung and the liver
G Varan, S Akkın, N Demirtürk… - Journal of drug …, 2021 - pubmed.ncbi.nlm.nih.gov
Erlotinib (ERL), a tyrosine kinase inhibitor approved for therapeutic use in non-small cell
lung cancer is further researched for eventual liver cancer treatment. However, conventional …
lung cancer is further researched for eventual liver cancer treatment. However, conventional …
Erlotinib entrapped in cholesterol-depleting cyclodextrin nanoparticles shows improved antitumoral efficacy in 3D spheroid tumors of the lung and the liver
G Varan, S Akkin, N Demirtürk, JM Benito, E Bilensoy - 2021 - digital.csic.es
Erlotinib (ERL), a tyrosine kinase inhibitor approved for therapeutic use in non-small cell
lung cancer is further researched for eventual liver cancer treatment. However, conventional …
lung cancer is further researched for eventual liver cancer treatment. However, conventional …
[PDF][PDF] Erlotinib entrapped in cholesterol-depleting cyclodextrin nanoparticles shows improved antitumoral efficacy in 3D spheroid tumors of the lung and the liver
G Varan, N Demirturk, J Benito… - Journal of Drug …, 2021 - avesis.hacettepe.edu.tr
Özet© 2020 Informa UK Limited, trading as Taylor & Francis Group. Erlotinib (ERL), a
tyrosine kinase inhibitor approved for therapeutic use in non-small cell lung cancer is further …
tyrosine kinase inhibitor approved for therapeutic use in non-small cell lung cancer is further …
Erlotinib entrapped in cholesterol-depleting cyclodextrin nanoparticles shows improved antitumoral efficacy in 3D spheroid tumors of the lung and the liver.
G Varan, S Akkın, N Demirtürk, JM Benito… - Journal of Drug …, 2020 - europepmc.org
Erlotinib (ERL), a tyrosine kinase inhibitor approved for therapeutic use in non-small cell
lung cancer is further researched for eventual liver cancer treatment. However, conventional …
lung cancer is further researched for eventual liver cancer treatment. However, conventional …